Retatrutide vs Tirzepatide: Mechanism Compared
Retatrutide and tirzepatide are both engineered incretin-receptor agonists from the same research lineage. The difference between them is one receptor — and which pathways that receptor opens up for study.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptor targets | GIP + GLP-1 + glucagon | GIP + GLP-1 |
| Class | Triple receptor agonist | Dual receptor agonist |
| Distinguishing arm | Adds the glucagon receptor | GIP + GLP-1 only |
| Development code | LY3437943 | LY3298176 |
| Research stage in literature | Phase 2 → phase 3 programs | Large phase 3 programs |
Both molecules activate the GIP and GLP-1 incretin receptors in a single peptide. Tirzepatide stops there — it is a dual agonist. Retatrutide adds a third arm, the glucagon receptor, making it a triple agonist.
That third receptor is the entire pharmacological distinction. In the published literature the glucagon arm is associated with hepatic and energy-expenditure pathways that the GIP/GLP-1 axis doesn't reach on its own — which is why retatrutide is studied as a separate question rather than simply a stronger version of the same thing.
For research purposes, the two are best understood as adjacent points on the same design progression: single-target (semaglutide) → dual (tirzepatide) → triple (retatrutide). Each added receptor broadens the set of metabolic pathways under study in one molecule.
This compares molecular mechanism and receptor class from the published literature only, not efficacy, potency, or outcomes. All Boulder Labs products are for laboratory research use only. Not for human consumption.
Common questions
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Retatrutide is a triple agonist that adds the glucagon receptor. The added glucagon-receptor activity is the defining pharmacological difference between the two research compounds.
Are retatrutide and tirzepatide in the same class?
Both are engineered incretin-receptor agonists in the same research lineage, but they are different classes: tirzepatide is a dual (GIP/GLP-1) agonist and retatrutide is a triple (GIP/GLP-1/glucagon) agonist.